Influence of fenflumizole on platelet aggregation in man.
The anti-aggregatory effect of fenflumizole, a new non-steroidal anti-inflammatory imidazole derivative is described in a study in 6 healthy male volunteers, mean age 33 years. Arachidonic acid (AA), ADP, collagen aggregation, coagulation and fibrinolysis parameters were examined before, during and after treatment with oral fenflumizole first 50 mg b.i.d. for 4.5 d and then 200 mg/d for 5 days. During treatment the threshold concentration for collagen aggregation demonstrated hypo-aggregability in all subjects. No significant change was noted in ADP aggregation. AA-induced aggregation showed an increased threshold concentration during and for 7 days after fenflumizole administration. No significant change was seen in bleeding time, fibrinolysis or coagulation parameters. No side effects were observed during or after treatment. It is concluded that fenflumizole is a potent inhibitor of platelet aggregation ex vivo.